Molecular Partners (MOLN) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$16.8M

Net income growth (year over year)

+34.70%

Net margin

—

Return on equity

−61.80%

EPS (trailing twelve months)

−$1.69

Book value per share

$1.89

P/E (trailing twelve months)

—

Price to book

1.93

Debt to assets

22.66%

Payout ratio

—

Dividend yield

—

Company profile

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

• How do I buy stock in Molecular Partners (MOLN)?

  MOLN trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.